Curaleaf Holdings, a vertically integrated multistate cannabis [and CBD] operator, is likely to face a wrongful death lawsuit, the latest in a string of lawsuits related to mislabeled products.
Curaleaf is currently facing 10 lawsuits from consumers who allegedly ingested an incorrectly labeled CBD tincture that contained “undisclosed levels of THC,” according to a product recall notice issued by the Oregon Liquor and Cannabis Commission (OLCC).
The recall was issued Sept. 21 for a single batch of the mislabeled CBD product, which was produced by Cura CS LLC and sold under Curaleaf’s Select brand. Curaleaf acquired Cura and its Select brand in 2019 in a $948.8-million all-stock deal.
Peter Clateman, Curaleaf chief legal officer, tells Cannabis Business Times and Hemp Grower that about 500 bottles from the batch were sold.
The OLCC expanded the recall Sept. 24 to include another Select tincture that said it contained 1,000 mg of THC on the label, but after a round of preliminary tests, the OLCC found that the product did not contain any detectable THC. According to OLCC, Curaleaf sold an estimated 630 units of the mislabeled tincture.
Curaleaf acknowledged the mislabeling of the two tinctures was caused by “human error.”
“So, the most